Telaprevir Improves and Shortens Hepatitis C Treatment
Share
Follow Us
The Editors at Hepatitis Central
August 11, 2010
Due to recently released Phase III trial results, telaprevir has a better chance of gaining FDA approval by 2011. Researchers found that adding telaprevir to pegylated interferon and ribavirin takes half the time to achieve superior results than does standard Hepatitis C therapy.
Vertex’s Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C
Ryan McBride 8/10/10
[Updated. 8:55 am Eastern time. See editor’s note.] Vertex Pharmaceuticals’s(NASDAQ:VRTX) lead drug candidate for hepatitis C infection has passed another test. The Cambridge, MA-based company, which has West Coast operations in San Diego, says today that it now has proof that its drug in combination with standard therapies can wipe out the chronic liver damaging disease about as well in 24 weeks as in 48 weeks.
Continue reading this entire article:
http://www.xconomy.com/boston/2010/08/10/vertexs-telaprevir-clears-hurdle-could-halve-treatment-times-for-hepatitis-c/
